Q-omics provides the consensus-scored TXNDC12 profile across patient tissues and cancer cell-line models. TXNDC12 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TXNDC12 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, TXNDC12 protein abundance shows 22,619 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, HNSC, and GBM as cancer lineages where TXNDC12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TXNDC12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TXNDC12 survival associations across molecular data types. TXNDC12 RNA expression shows survival associations in the most cancer types (25), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TXNDC12 RNA expression–survival associations across cancer types. High TXNDC12 expression shows unfavorable associations in KIRP, HNSC, LIHC, ACC, MESO and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TXNDC12 RNA expression.
This table summarizes TXNDC12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TXNDC12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TXNDC12 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, BLCA, KIRP and LIHC. The HNSC box plot shows higher TXNDC12 RNA expression in tumor versus normal tissue (log2 FC = +1.418, t-test p < 0.001).
This table shows molecular features associated with TXNDC12 in patient tissues and cancer cell lines. In patient samples, TXNDC12 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TXNDC12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Lymphoma.
